Pancreatic cancer

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Retrieved on: 
Friday, September 13, 2024
Well, Master of Science, BID, Patient, Therapy, Safety, BRAF, Oncology, Clinical trial, Caregiver, Webcast, PD, CCCC, ESMO, MEK, Cetuximab, Pharmacokinetics, Neoplasm, Congress, Colorectal cancer, BRAF V600, Teaching hospital, Completeness, Pancreatic cancer, RECIST, Cancer, Mutation, Liver disease, Lung cancer, EGFR, Melanoma, Vall, Pharmaceutical industry

Taken together, these data support our hypothesis that degradation may offer a new therapeutic option over inhibition for BRAF V600 mutant solid tumors,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics.

Key Points: 
  • Taken together, these data support our hypothesis that degradation may offer a new therapeutic option over inhibition for BRAF V600 mutant solid tumors,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics.
  • Prior therapy must include a BRAF inhibitor, unless access is limited by regional regulatory approvals or reimbursement.
  • Patients received a median of three prior therapies; 35 patients (97 percent) had received prior BRAF inhibitor therapy.
  • Pharmacokinetics (PK) and Pharmacodynamics (PD): Initial data demonstrating dose-dependent bioavailability and degradation of BRAF V600E protein support CFT1946 proof of mechanism.

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Retrieved on: 
Friday, September 13, 2024
Summit, Patient, Therapy, Doctor of Philosophy, Pancreatic cancer, Conference, Cancer, Death, Research and development, Drug development, Neoplasm, Risk, Development, Pharmaceutical industry

BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced upcoming presentations in September and October.

Key Points: 
  • BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced upcoming presentations in September and October.
  • Dr. Eileen O’Reilly of Memorial Sloan Kettering Cancer Center will include recent Phase I AMPLIFY-7P trial updates in her keynote lecture.
  • The second presentation will take place at the RAS-Targeted Drug Development Summit being held September 25, 2024, in Boston, Massachusetts.
  • Dr. Pete DeMuth, Ph.D., Chief Scientific Officer of Elicio Therapeutics, will present on the clinical translation of the Elicio RAS-targeted Amphiphile vaccines.

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Retrieved on: 
Thursday, September 12, 2024
AACR, Pleural effusion, Patient, RAS, Safety, Unk, MAPK, Therapy, PD, Ascites, Partial, DSMB, Radiology, Hospital, Paclitaxel, Symantec Endpoint Protection, Data monitoring committee, Partnership, Gemcitabine, Pancreatic cancer, RECIST, Plasma, Mayo Clinic Cancer Center, E pluribus unum, Lung cancer, Mayo Clinic, Oncology, NSCLC, Pharmaceutical industry

The Phase 2a portion includes five arms, one of which focuses on patients with RAS mutant melanoma, another on patients with RAS mutant non-small cell lung cancer (NSCLC), and three arms focused on patients with pancreatic cancer.

Key Points: 
  • The Phase 2a portion includes five arms, one of which focuses on patients with RAS mutant melanoma, another on patients with RAS mutant non-small cell lung cancer (NSCLC), and three arms focused on patients with pancreatic cancer.
  • Immuneering previously announced that IMM-1-104 received fast track designation for the treatment of first- and second-line pancreatic cancer.
  • Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
  • Initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.

Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy

Retrieved on: 
Thursday, September 12, 2024
Pediatrics, CD3, Research, Patient, Safety, DSM-IV codes, FDA, Drive, Drive Capital, Novartis, Carcinoma, Food, Acute lymphoblastic leukemia, Stomach, Immunotherapy, BCMA, Liver, Science Advances, Cancer, Toxicity, Hospital, Biotechnology, AAV, Pancreatic cancer, Breast cancer, Nationwide, Division, CD19, SAN, IND, Novartis Gene Therapies, Vaccine

Vironexis’s $26 million seed financing was led by Drive Capital and Future Ventures, with participation from Moonshots Capital and Capital Factory.

Key Points: 
  • Vironexis’s $26 million seed financing was led by Drive Capital and Future Ventures, with participation from Moonshots Capital and Capital Factory.
  • Vironexis anticipates initiating patient enrollment of a Phase 1/2 trial of VNX-101 in the fourth quarter of 2024, which will mark the first-ever clinical trial of an AAV-delivered cancer immunotherapy.
  • VNX-101 has received both Fast Track Designation and Rare Pediatric Disease Designation from the FDA.
  • “We’re excited to launch Vironexis from stealth and reveal our noteworthy progress advancing AAV-delivered T-cell immunotherapy,” said Samit Varma, co-founder and CEO of Vironexis.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN

Retrieved on: 
Tuesday, September 10, 2024
Titan, Class, Court, Melanoma, Advertising, Pancreatic cancer, Tobacco

WHAT TO DO NEXT: To join the Agenus class action, go to https://rosenlegal.com/submit-form/?case_id=28683 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Agenus class action, go to https://rosenlegal.com/submit-form/?case_id=28683 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc.

Retrieved on: 
Tuesday, September 10, 2024
News, Drug, MSS, Patient, Person, FDA, LLP, BAL, Complaint, Viability, Melanoma, Food, Immunotherapy, NLM, Colorectal cancer, Pancreatic cancer, Survival, BOT, SAN, CRC, Pharmaceutical industry

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024.

Key Points: 
  • SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024.
  • Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. and internationally.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Global Oncolytic Virus Immunotherapy Market: $1.5 Billion Opportunity & Clinical Trials Insights 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 10, 2024
Pharmaceutical, Science, Health, Research, EMA, Virus, Investment, Irinotecan, Fast Track, H101, Antibody, Patient, Potyvirus, Therapy, Snow, Astellas Pharma, FDA, Nanoparticle, Growth, Genelux Corporation, Pembrolizumab, Laboratory, Cancer, Glioma, PD-1, Melanoma, PD-L1, Optimism, Government, NRG, Immunotherapy, Quality of life, Attention, Merck, Roche, OH2, Head, Oncos, PRIME, Pancreatic cancer, Breast cancer, Candel, Gastrointestinal cancer, Indication, Bristol Myers Squibb, Immune system, Vaccine

The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.
  • Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy.
  • Oncolytic virus immunotherapy complements these approaches by utilizing viruses to stimulate an immune response against cancer cells.
  • Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion by 2030
    Oncolytic Viruses Immunotherapies Clinical Trials by Company, Indication & Phase
    Comprehensive Insight on Oncolytic Virus Immunotherapies in Clinical Trials: > 180 Therapies
    2.2 FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME

SCbio's Life Sciences Accelerator, SCbioDrive, Announces Inaugural Cohort of Oncology and Neuroscience Startups

Retrieved on: 
Tuesday, September 10, 2024
Lung cancer, Eli Lilly, Curriculum, Alzheimer's disease, Leukemia, Patient, Melrose, Charles River Laboratories, B cell, Frontotemporal dementia, Growth, Therapy, Mentorship, Gene, CRPC, Prostate, Homeostasis, Harvard Medical School, NEPC, Partnership, VIT, Biomarker, Pancreatic cancer, Risk, Parkinson's disease, Lymphoma, IND, Jaya, Pharmaceutical industry

GREENVILLE, S.C., Sept. 10, 2024 /PRNewswire/ -- SCbio, in partnership with The Massachusetts Biotechnology Council (MassBio), has selected seven emerging life sciences companies to participate in the inaugural SCbioDrive Accelerator cohort.

Key Points: 
  • "We are thrilled to welcome this exceptional cohort of oncology and neuroscience companies to SCbioDrive," said SCbio President and CEO James Chappell.
  • By bringing together these world-class innovators, we're not only advancing critical scientific breakthroughs but also shining a spotlight on South Carolina as a hub for life sciences innovation and collaboration."
  • These startups will participate in business-focused curriculum modules taught by experts including Charles River Labs , Deloitte , Eli Lilly , Maynard Nexsen , Medpoint , Inspire Agency and more.
  • VIT's lead program is at the IND-enabling stage and focuses on restoration of neuronal nicotinamide adenine dinucleotide homeostasis and cell recovery.

Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

Retrieved on: 
Tuesday, September 10, 2024
SOC, CM24, AACR, Patient, Nivolumab, Pancreatic cancer, Conference, PD-1, Annual general meeting, Cancer, Interim, Drug resistance, Escape Room, PFS, Research, Society, ASCO, PDAC, Pharmaceutical industry

Purple Biotech’s poster titled, “Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer” will be presented during a poster session on Tuesday, September 17 from 6:45-9:00 pm ET.

Key Points: 
  • Purple Biotech’s poster titled, “Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer” will be presented during a poster session on Tuesday, September 17 from 6:45-9:00 pm ET.
  • The Company’s Phase 2 study is evaluating CM24 in combination with Bristol Myers Squibb's PD-1 inhibitor nivolumab plus standard of care (SoC) chemotherapy in second line pancreatic ductal adenocarcinoma (PDAC) patients compared to SoC chemotherapy alone.
  • Sixty-three patients have been enrolled in the randomized study across 18 centers in the U.S., Spain, and Israel.
  • Topline data are expected in the fourth quarter of 2024.

Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Retrieved on: 
Monday, September 9, 2024
Class Action Lawsuit, Professional Services, Legal, Melanoma, Pancreatic cancer, Business operations, Advertising

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024.

Key Points: 
  • Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024.
  • The Allegations: Rosen Law Firm is Investigating the Allegations that Agenus Inc. (NASDAQ: AGEN) Misled Investors Regarding its Business Operations.
  • About Rosen Law: Some law firms issuing releases about this matter do not actually litigate securities class actions; Rosen Law Firm does.
  • A recognized leader in shareholder rights litigation, the attorneys and staff of Rosen Law Firm have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing.